Multi-Asset Product Portfolio for Treatment of Various Cancers
Our proprietary phospholipid ether (PLE) platform technology features include the capacity to link to a wide variety of warheads, provide a significant increase in targeted oncologic warhead delivery and the ability to target all tumor cells. As a result, we're working to generate Phospholipid Drug Conjugates™ (PDCs) to treat a broad range of cancers with the potential to improve the therapeutic index of oncologic drug warheads, enhance or maintain efficacy while reducing adverse events by minimizing drug delivery to healthy cells, and increasing delivery to cancerous cells and cancer stem cells.
PDC Proprietary Product Pipeline
| PDC Program | Warhead/ Mechanism of Action |
Indication | Discovery | Pre-Ind | Phase 1 | Phase 2 | Collaboration |
|---|---|---|---|---|---|---|---|
| CLR 131 | Iodine-131 DNA Damage |
Multiple Myeloma |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
|
| B-Cell Lymphomas |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase complete
|
Phase 2 Phase in progress
|
|||
| Pediatric |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
 |
||
| Head & Neck |
Discovery Phase complete
|
Pre-Ind Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
 |
||
| CLR 1900 | Proprietary Cell Cycle Arrest |
Solid Tumors |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Partnerships
| PDC Program | Warhead/ Mechanism of Action |
Indication | Discovery | Pre-Ind | Phase 1 | Phase 2 | Collaboration |
|---|---|---|---|---|---|---|---|
| CLR 1800 | Proprietary Translation Inhibition |
Solid Tumors |
Discovery Phase complete
|
Pre-Ind Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
 |
| CLR 2000 | Proprietary Cytoskeleton Disruption |
Performance-Based |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
 |
| CLR 2100 | Proprietary Ribosomal Inhibitor |
Solid Tumors |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
 |
| CLR 2200 | Proprietary Tubulin Disruption |
Solid Tumors |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
 |
| CLR 12120 | Solid Tumors |
Discovery Phase in progress
|
Pre-Ind Phase not started
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
 |
Proprietary Products
CLR 131
CLR 131 is a small-molecule, targeted PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells. CLR 131 is our lead therapeutic PDC product candidate and is currently being evaluated in multiple Phase 2 and Phase 1 clinical studies.
View Candidate
CLR 1900
CLR 1900 series is another internally developed proprietary PDC program leveraging a novel class of small molecule cytotoxic compounds as the warhead. The warhead functions by targeting a validated pathway that results in the inhibition of cell division and thereby killing the tumor cells. This series of molecules could produce a product candidate targeted to select solid tumors. Currently, the program is in early preclinical development.
Partnered Products
CLR 1800
CLR 1800 Series was a collaborative PDC program with Pierre Fabre that expired in January 2019. The program has been successful in demonstrating improved tolerability and efficacy in multiple animal models. The newly developed PDCs may provide enhanced therapeutic indices to otherwise highly potent, nontargeted payloads through the targeted delivery of the chemotherapeutic payload to cancer cells via our proprietary phospholipid ether delivery platform. The CLR 1800 Series remains under evaluation by us as a number of PDC molecules have the potential to be progressed toward and into IND enabling studies.
CLR 2000
CLR 2000 series is part of a collaborative PDC program with Avicenna Oncology, a leading developer of antibody drug conjugates (ADCs). The objective of the research collaboration is to design and develop a series of PDCs utilizing Avicenna Oncology’s proprietary cytotoxic warhead. Although Avicenna Oncology is a leading developer of ADCs, this collaboration was sought as a means to overcome many of the challenges associated with ADCs, including those associated with the targeting of specific cell surface epitopes.
CLR 2100 and 2200
CLR 2100 and 2200 series are part of a collaborative PDC programs with Onconova Therapeutics, Inc., a biotechnology company specializing in the discovery and development of novel small molecule cancer therapies. The collaboration is structured such that we will design and develop a series of PDCs utilizing different small molecules that Onconova Therapeutics is developing as the warheads with the intent to show improved targeting and specificity to the tumor. Onconova Therapeutics has previously taken at least one of the molecules into Phase 1 clinical trials.